[Efficacy of stanozolol and danazol in the treatment of non-severe aplastic anemia and their effects on CD4(+)CD25(+)Foxp3(+) regulatory T cells].

H M Li; Ziwen Long; Tiantian Wang; Bing Han

doi:10.3760/cma.j.issn.0253-2727.2022.02.013

[Efficacy of stanozolol and danazol in the treatment of non-severe aplastic anemia and their effects on CD4(+)CD25(+)Foxp3(+) regulatory T cells].

H M Li, Ziwen Long, Tiantian Wang, Bing Han

In: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022 · vol. 43(2) , pp. 157–160 · doi:10.3760/cma.j.issn.0253-2727.2022.02.013 · PMID:35381679 · W4223980960

article OA: green CC0 ⤵ 1 in-corpus citation

🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Danazol as first-line therapy for aplastic anemia via openalex
Danazol increases T regulatory cells in patients with aplastic anemia via openalex
Danazol Suppresses the Production of Interleukin‐1β and Tumor Necrosis Factor by Human Monocytes via openalex
Danazol therapy for aplastic anemia refractory to immunosuppressive therapy via openalex
Immunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study via openalex
Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia via openalex
W44318375 via openalex
doi:10.1053/j.seminhematol.2014.10.002 via openalex
doi:10.1056/nejmra1413485 via openalex
doi:10.1002/cam4.1953 via openalex
doi:10.1016/j.immuni.2009.03.019 via openalex
doi:10.1007/s12185-010-0601-1 via openalex
doi:10.3760/cma.j.issn.0253-2727.2017.01.001 via openalex
doi:10.1182/blood-2016-08-693481 via openalex
doi:10.1182/blood-2006-01-0329 via openalex
doi:10.1016/s0140-6736(87)91432-2 via openalex
doi:10.1111/bjh.13853 via openalex
doi:10.1016/s0140-6736(04)16724-x via openalex
doi:10.1097/tp.0b013e318166910b via openalex
doi:10.1182/blood-2011-11-390708 via openalex
doi:10.1046/j.1365-2141.2000.02289.x via openalex
doi:10.1016/0090-1229(87)90016-x via openalex
doi:10.2169/internalmedicine.37.235 via openalex
doi:10.3760/cma.j.issn.0253-2727.2016.11.004 via openalex
doi:10.4049/jimmunol.172.9.5287 via openalex
W23158175 via openalex

Cited by (1)

Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy 2025

Source provenance

openalex: last seen: 2026-05-10T10:44:09.809153+00:00

License: CC0 · commercial use OK

[1] Danazol as first-line therapy for aplastic anemia via openalex

[2] Danazol increases T regulatory cells in patients with aplastic anemia via openalex

[3] Danazol Suppresses the Production of Interleukin‐1β and Tumor Necrosis Factor by Human Monocytes via openalex

[4] Danazol therapy for aplastic anemia refractory to immunosuppressive therapy via openalex

[5] Immunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study via openalex

[6] Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia via openalex

[7] W44318375 via openalex

[8] doi:10.1053/j.seminhematol.2014.10.002 via openalex

[9] doi:10.1056/nejmra1413485 via openalex

[10] doi:10.1002/cam4.1953 via openalex

[11] doi:10.1016/j.immuni.2009.03.019 via openalex

[12] doi:10.1007/s12185-010-0601-1 via openalex

[13] doi:10.3760/cma.j.issn.0253-2727.2017.01.001 via openalex

[14] doi:10.1182/blood-2016-08-693481 via openalex

[15] doi:10.1182/blood-2006-01-0329 via openalex

[16] doi:10.1016/s0140-6736(87)91432-2 via openalex

[17] doi:10.1111/bjh.13853 via openalex

[18] doi:10.1016/s0140-6736(04)16724-x via openalex

[19] doi:10.1097/tp.0b013e318166910b via openalex

[20] doi:10.1182/blood-2011-11-390708 via openalex

[21] doi:10.1046/j.1365-2141.2000.02289.x via openalex

[22] doi:10.1016/0090-1229(87)90016-x via openalex

[23] doi:10.2169/internalmedicine.37.235 via openalex

[24] doi:10.3760/cma.j.issn.0253-2727.2016.11.004 via openalex

[25] doi:10.4049/jimmunol.172.9.5287 via openalex

[26] W23158175 via openalex